Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | DHPS | P49366 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293249 | 0.88 | EDNRB (0.44) | KDM4EEDNRB | |
| SCHEMBL7209287 | 0.83 | EDNRA (0.49) | EDNRAKDM4EALDH1A1EDNRBABCC3 | |
| SCHEMBL6289621 | 0.82 | EDNRA (0.48) | EDNRAKDM4EALDH1A1EDNRBABCC3 | |
| SCHEMBL6292787 | 0.78 | EDNRA (0.44) | EDNRAALDH1A1EDNRBABCC3ABCC4 | |
| SCHEMBL7223045 | 0.78 | EDNRB (0.47) | EDNRAEDNRB | |
| SCHEMBL6289631 | 0.76 | EDNRA (0.41) | EDNRAKDM4EALDH1A1EDNRB | |
| SCHEMBL7303422 | 0.75 | EDNRA (0.71) | EDNRAEDNRB | |
| SCHEMBL7318413 | 0.72 | EDNRB (0.45) | EDNRB | |
| SCHEMBL7317941 | 0.72 | EDNRB (0.45) | EDNRB | |
| SCHEMBL7205015 | 0.72 | EDNRB (0.54) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | EDNRA 2/4885KDM4E 3618/4885ALDH1A1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.